Literature DB >> 10532690

Peripheral blood mononuclear cell production of interleukin-8 and IL-8-dependent neutrophil function in hypercholesterolemic patients.

E Porreca1, R Sergi, G Baccante, M Reale, L Orsini, C D Febbo, G Caselli, F Cuccurullo, R Bertini.   

Abstract

Interleukin-8 is a cytokine produced by mononuclear cells that is involved in polymorphonuclear neutrophil leukocyte (PMN) recruitment and activation. Several studies have previously demonstrated a leukocyte activation during hypercholesterolemia and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have been found to play a role in the prevention of atherothrombotic disease. The purpose of this study was to determine interleukin-8 (IL-8) mRNA expression and ex vivo production from peripheral blood mononuclear cells (PBMCs) and IL-8-dependent PMN activation of hypercholesterolemic (HC) patients with respect to normocholesterolemic (NC) subjects. Using Northern blot analysis, we found a four- and threefold increase in the amount of IL-8 transcript in PBMC from HC patients, in unstimulated and LPS stimulated cultures, respectively. A specific immunoassay showed a correspondingly significant increase of IL-8 immunoactivity in the conditioned medium of PBMC from HC subjects as compared with controls (unstimulated PBMC: 15 +/- 4 vs. 4.2 +/- 3 ng/ml; P < 0.0001; LPS stimulated PBMC: 65.3 +/- 8 vs. 36.6 +/- 9 ng/ml; P < 0.0001). PMN of HC patients stimulated with IL-8 showed a reduced elastase release with respect to NC subjects before physiological granule release after f-Met-Leu-Phe (fMLP) treatment. These results indicate an upregulation of the IL-8 system in dyslipidemic patients and provide evidence for ongoing in vivo IL-8-dependent PMN activation during hypercholesterolemia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10532690     DOI: 10.1016/s0021-9150(99)00160-4

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

1.  MCP-1 and MIP-2 expression and production in BB diabetic rat: effect of chronic hypoxia.

Authors:  Cacchio Marisa; Isabella Lucci; Camillo Di Giulio; Giuseppina Bianchi; Alfredo Grilli; Antonia Patruno; Marcella Reale
Journal:  Mol Cell Biochem       Date:  2005-08       Impact factor: 3.396

2.  Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression.

Authors:  William A Boisvert; David M Rose; Kristen A Johnson; Maria E Fuentes; Sergio A Lira; Linda K Curtiss; Robert A Terkeltaub
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

Review 3.  Obesity and nutrition in acute respiratory distress syndrome.

Authors:  Renee D Stapleton; Benjamin T Suratt
Journal:  Clin Chest Med       Date:  2014-09-24       Impact factor: 2.878

4.  Predictive Value of IL-8 for Sepsis and Severe Infections After Burn Injury: A Clinical Study.

Authors:  Robert Kraft; David N Herndon; Celeste C Finnerty; Robert A Cox; Juquan Song; Marc G Jeschke
Journal:  Shock       Date:  2015-03       Impact factor: 3.454

5.  Angiogenic transcriptome of human microvascular endothelial cells: Effect of hypoxia, modulation by atorvastatin.

Authors:  Agnieszka Loboda; Agnieszka Jazwa; Alicja Jozkowicz; Grietje Molema; Jozef Dulak
Journal:  Vascul Pharmacol       Date:  2006-02-14       Impact factor: 5.773

6.  Effects of acute and chronic low density lipoprotein exposure on neutrophil function.

Authors:  Tatsiana Palvinskaya; Maryellen Antkowiak; Elianne Burg; Christopher C Lenox; Niki Ubags; Angela Cramer; Mercedes Rincón; Anne E Dixon; Michael B Fessler; Matthew E Poynter; Benjamin T Suratt
Journal:  Pulm Pharmacol Ther       Date:  2012-10-17       Impact factor: 3.410

7.  Cytokine secretion responsiveness of lymphomonocytes following cortisol cell exposure: Sex differences.

Authors:  Eleonora Da Pozzo; Chiara Giacomelli; Chiara Cavallini; Claudia Martini
Journal:  PLoS One       Date:  2018-07-26       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.